RxDoctor Payments DataLook up a doctor →

George Urban, MD

Internal Medicine · Chicago, ILNPI 1639161524

Payments from drug & device makers

$258,387in general payments, 2019–2025

Across 1,178 payments — averaging $219.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$73K
  • AbbVie$70K
  • Amgen$40K
  • Teva Pharmaceuticals USA, Inc.$29K
  • Axsome Therapeutics, Inc.$25K
  • Impel Pharmaceuticals LLC$5K
  • plus $17K from 32 others

What the payments were for

  • Consulting fees$18,7037%
  • Speaking & faculty fees$203,75179%
  • Grants$440%
  • Travel & lodging$12,0935%
  • Food & beverage$23,6039%
  • Education$1950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,387 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$283,059
Medicare patients
196
Services billed
19,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate90$122,702
UbrelvyUbrogepant75$113,090
QuliptaAtogepant80$101,602
Aimovig AutoinjectorErenumab-Aooe70$68,138
Emgality PenGalcanezumab-Gnlm79$65,329
Emgality SyringeGalcanezumab-Gnlm35$57,175
Ajovy SyringeFremanezumab-Vfrm27$31,491
VraylarCariprazine Hcl13$19,873
ReyvowLasmiditan Succinate14$16,064
Diphenhydramine Hcl252$6,705
Sumatriptan Succinate73$5,013
Levetiracetam128$3,584
Eletriptan HbrEletriptan Hydrobromide24$3,412
Orphenadrine Citrate24$3,339
Bupropion XlBupropion Hcl48$2,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Vraylar$70,046$234,566168 claims
PfizerNurtec Odt$1,228$122,70290 claims
Lilly USA, LLCReyvow$72,619$16,06414 claims
Upsher-smith Laboratories LLCTopiramate$395$1,298123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →